Business Description
Intra-Cellular Therapies Inc
NAICS : 325412
SIC : 2834
ISIN : US46116X1019
Compare
Compare
Traded in other countries / regions
ITCI.USA23I.GermanyI2TC34.BrazilITCI.Mexico IPO Date
2013-12-19Description
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 29.4 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 31.64 | |||||
| Beneish M-Score | 220.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 147 | |||||
| 3-Year EBITDA Growth Rate | 20.3 | |||||
| 3-Year EPS without NRI Growth Rate | 23.3 | |||||
| 3-Year FCF Growth Rate | 26.5 | |||||
| 3-Year Book Growth Rate | -9.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 291.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 42.31 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.19 | |||||
| 9-Day RSI | 55.42 | |||||
| 14-Day RSI | 55.38 | |||||
| 6-1 Month Momentum % | 40.37 | |||||
| 12-1 Month Momentum % | 10.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.41 | |||||
| Quick Ratio | 5.31 | |||||
| Cash Ratio | 4.03 | |||||
| Days Inventory | 321.87 | |||||
| Days Sales Outstanding | 74.14 | |||||
| Days Payable | 105.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.2 | |||||
| Shareholder Yield % | 0.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.7 | |||||
| Operating Margin % | -34.49 | |||||
| Net Margin % | -30.22 | |||||
| FCF Margin % | -26.87 | |||||
| ROE % | -22.65 | |||||
| ROA % | -19.2 | |||||
| ROIC % | -122.51 | |||||
| ROC (Joel Greenblatt) % | -161.6 | |||||
| ROCE % | -25.26 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 15.06 | |||||
| PB Ratio | 11.71 | |||||
| Price-to-Tangible-Book | 11.71 | |||||
| EV-to-EBIT | -44.99 | |||||
| EV-to-Forward-EBIT | -69.36 | |||||
| EV-to-EBITDA | -45.14 | |||||
| EV-to-Forward-EBITDA | -77.01 | |||||
| EV-to-Revenue | 15.51 | |||||
| EV-to-Forward-Revenue | 10.83 | |||||
| EV-to-FCF | -58.3 | |||||
| Price-to-Net-Current-Asset-Value | 13 | |||||
| Price-to-Net-Cash | 19.11 | |||||
| Earnings Yield (Greenblatt) % | -2.22 | |||||
| FCF Yield % | -1.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ITCI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Intra-Cellular Therapies Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 462.175 | ||
| EPS (TTM) ($) | -1.46 | ||
| Beta | 0.88 | ||
| Volatility % | 36.81 | ||
| 14-Day RSI | 55.38 | ||
| 14-Day ATR ($) | 3.638176 | ||
| 20-Day SMA ($) | 70.0805 | ||
| 12-1 Month Momentum % | 10.88 | ||
| 52-Week Range ($) | 45.5 - 84.89 | ||
| Shares Outstanding (Mil) | 104.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intra-Cellular Therapies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Intra-Cellular Therapies Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Intra-Cellular Therapies Inc Frequently Asked Questions
What is Intra-Cellular Therapies Inc(ITCI)'s stock price today?
The current price of ITCI is $71.88. The 52 week high of ITCI is $84.89 and 52 week low is $45.50.
When is next earnings date of Intra-Cellular Therapies Inc(ITCI)?
The next earnings date of Intra-Cellular Therapies Inc(ITCI) is 2024-05-03 Est..
Does Intra-Cellular Therapies Inc(ITCI) pay dividends? If so, how much?
Intra-Cellular Therapies Inc(ITCI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers